NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee C) meeting minutes

### Minutes: Confirmed

### Date and Time: Tuesday 2 June 2020 at 9:30am (Held via Zoom)

### Committee members Present:

* Chair Stephen O’Brien Present for all notes
* Vice Chair Peter Selby Present for all notes
* Alex Cale Present for all notes
* Michael Chambers Present notes 10 to 27
* Prithwiraj Das Present for all notes
* Rob Forsyth Present for all notes
* David Foreman Present for all notes
* Natalie Hallas Present for all notes
* John Hampson Present for all notes
* Nigel Langford Present for all notes
* Andrea Manca Present for all notes
* Iain McGowan Present for all notes
* Kirandip Moyo Present for all notes
* Richard Nicholas Present for all notes
* Ugochinyere Nwulu Present for all notes
* Stella O'Brien Present for all notes
* Subhash Pokhrel Present for all notes
* Lindsay Smith Present for notes 10 to 18
* Matthew Stevenson Present for notes 10 to 27
* Paul Tappenden Present for notes 10 to 23
* Derek Ward Present for all notes

### In attendance:

* Helen Knight, Programme Director, NICE, Present for all notes
* Jasdeep Hayre, Associate Director, NICE, Present for notes 1 to 18
* Linda Landalls, Associate Director, NICE, Present for notes 19 to 27
* Gavin Kenny, Project Manager, NICE, Present for notes 1 to 9
* Kate Moore, Project Manager, NICE, Present for notes 10 to 27
* Natalie Spray, Project Manager, NICE, Present for all notes
* Jenna Dilkes, Programme Manager, NICE Present for all notes
* Mandy Brereton, Assistant Project Manager, NICE, Present for all notes
* Gemma Smith Coordinator, NICE, Present for all notes
* Ismahan Abdullah, Administrator, NICE, Present for notes 1 to 9
* Celia Mayers, Administrator, NICE, Present for notes 10 to 27
* Orsolya Balough, Technical Analyst, NICE, Present for notes 19 to 27
* Luke Cowie, Technical Analyst, NICE, Present for notes 1 to 9
* Ewa Rupniewska, Technical Analyst, Present for notes 10 to 18
* Sally Doss, Technical Adviser, NICE, Present for notes 1 to 9
* Jamie Elvidge, Technical Adviser, NICE, Present for notes 10 to 18
* Alex Filby, Technical Adviser, NICE, Present for notes 19 to 27
* Isaac Corro Ramos, Kleijnen Systematic Reviews, Evidence Review Group, Present for notes 1 to 6
* Robert Wolff, Kleijnen Systematic Reviews, Evidence Review Group, Present for notes 1 to 6
* Marty Chaplin, LRiG, Evidence Review Group, Present for notes 10 to 14
* James Mahon, LRiG, Evidence Review Group, Present for notes 10 to 14
* Aline Navega Biz, ScHARR, Evidence Review Group, Present for notes 19 to 23
* Paul Tappenden, ScHARR, Evidence Review Group, Present for notes 19 to 23
* Kate Cwynarski, Clinical Expert, Present for notes 1 to 6
* Christopher Fox, Clinical Expert, Present for notes 1 to 6
* Mike Dennis, Clinical Expert, Present for notes 19 to 23
* Ruth Pettengell, Clinical Expert, Present for notes 1 to 6
* Nigel Russell, Clinical Expert, Present for notes 19 to 23
* Jonathan Morgan, Patient Expert, Present for notes 1 to 6
* Steven Scowcroft, Patient Expert, Present for notes 1 to 6
* Marcus Williams, Patient Expert, Present for notes 1 to 6
* Prof Peter Clark, Cancer drugs Fund Clinical Lead, Present for notes 10 to 27

## Non-public attendees:

* Esther Clifford, NICE Observer, Present for notes 10 to 27
* Emilene Coventry, Editor, NICE, Present for all notes
* Henry Edwards, NICE Observer, Present for all notes
* Sara Buckner, NICE Observer, Present for all notes
* Olivia Crane, NICE Observer, Present for all notes
* Keona Bennett, NICE Observer, Present for all notes
* Robby Richey, NICE Observer, Present for all notes
* George Millington, NICE Observer, Present for all notes
* Sophie McHugh, NICE Observer, Present for all notes
* Izabela Syrek, NICE Observer, Present for notes 1 to 9
* Lee Berry, NICE Observer, Present for notes 1 to 9
* Mandy Tonkinson, Public Involvement adviser, for notes 1 to 6
* Nicola Cunliffe, NICE Observer, NICE, Present for all notes
* Anthony Gildea, NICE Observer, NICE, Present for notes 1 to 9
* Laura Marsden, NICE Observer, NICE, Present for notes 1 to 9
* Victoria Fitton, NICE Observer, NICE, Present for notes 1 to 9
* Sabina Keane, NICE Observer, NICE, Present for notes 1 to 9
* Sarah Bromley, NICE Observer, NICE, Present for notes 1 to 9
* Holly Cranmer, Company Representative, Present for notes 1 to 6
* Tanja Podkonjak, Company Representative, Present for notes 1 to 6
* Sarah Breen, Company Representative, Present for notes 10 to 14
* Younan Zhang, Company Representative, Present for notes 10 to 14
* Andy Garnham, Company Representative, Present for notes 19 to 23
* Hanna Sodatanou, Company Representative, Present for notes 19 to 23

### Notes

### Any other Business

1. None

## Appraisal of Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma [ID1586]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Takeda.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

	1. Prithwiraj Das declared a non-financial and personal interest as he works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Lytics). He also declared he has not worked on any of the indications under investigation in the last 12 months.
		1. It was agreed that this declaration **would not** prevent Prithwiraj from participating on this topic.
	2. Ruth Pettengell declared indirect interests as she worked on an advisory board for Takeda.
		1. It was agreed that this declaration **would not** prevent Ruth from participating on this topic
	3. Kate Cwynarski declared direct financial interests as she worked in a consulting/advisory role for Takeda and attended conferences and received travel support from Roche.
		1. It was agreed that this declaration **would not** prevent Kate from participating on this topic.
	4. Christopher Fox declared direct financial interests as he was a remunerated expert clinical advisor for and received travel/accommodation support from Takeda he also provided research support to Department of Clinical Haematology, Nottingham University Hospitals NHS Trust
		1. It was agreed that this declaration **would not** prevent Christopher from participating on this topic.
	5. Steven Scowcroft declared indirect interests as Lymphoma Action are supported by pharma organisations including the one involved with this HTA.
		1. It was agreed that this declaration **would not** prevent Steven from participating on this topic.
	6. Mike Chambers was directly conflicted and therefore prevented from participating on this topic.
		1. Conflict – has a long-term contract with the sponsor providing support and advice concerning Innovative Medicines Initiative (IMI) projects and some Outcomes Research activities. He also stated that he has not engaged with any activities or advice related to brentuximab vedotin (for any indications)
	7. Matthew Stevenson was directly conflicted and therefore prevented from participating on this topic.
		1. Conflict - financial interests as he contributed to an advisory board.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer [ID1140]**

**Part 1 – Open session**

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)representatives and representatives from Merck Sharp & Dohme.
2. The Chair asked all committee members, expert, ERG representatives and NICE staff present to declare any relevant interests

	1. Prithwiraj Das declared non-financial and personal interest. As he works at as he works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Lytics). He also declared he has not worked on any of the indications under investigation in the last 12 months.
		1. It was agreed that this declaration **would not** prevent Prithwiraj from participating on this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

## Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. A vote was taken on the decision to recommend for non-oral subgroup. The options were:
Option 1: Yes
Option 2: No
The committee voted for Option 2
4. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]**

**Part 1 – Open session**

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Astellas Pharma.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

	1. Mike Chambers declared a financial interest, in 2019 he provided a consultancy to the sponsor on evidence generation and economic evaluation, however these were unrelated to this topic
		1. It was agreed that this declaration would not prevent Mike from participating in this section of the meeting, but it was noted he would not be a voting member of committee for this topic.
	2. Matthew Stevenson declared non-financial & personal interests as he is a director of ScHARR.
		1. It was agreed that this declarationwould not prevent Matthew from participating in this section of the meeting.
	3. Paul Tappenden declared a Non-Financial & Personal interest as he will be representing the ERG for this topic,
		1. It was agreed this declaration would not prevent Paul from participating in this part of the meeting.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)**

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
3. The committee decision was based on consensus.
4. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.